Abbvie Inc

NYSE:ABBV  
109.36
+0.45 (+0.41%)
4:00:00 PM EDT: $109.36 0.00 (0.00%)
Products

AbbVie Submits Regulatory Applications to FDA, EMA for Rinvoq for Treatment of Ulcerative Colitis

Published: 09/16/2021 12:20 GMT
Abbvie Inc (ABBV) - Abbvie Submits Regulatory Applications to FDA and Ema for Upadacitinib (rinvoq®) for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis.
Abbvie Submits Regulatory Applications to FDA and Ema for Upadacitinib (rinvoq®) for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis.
Abbvie Inc - Safety Results Were Generally Consistent With Known Safety Profile of Upadacitinib, With No New Important Safety Risks Observed.
Abbvie Inc - Significantly More Upadacitinib Patients Achieved Primary, All Secondary Endpoints Versus Placebo in Phase 3 Induction, Maintenance Studies Supporting Submissions.